Arcturus Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline Progress

ARCT-154 Phase 3 COVID-19 booster trial achieved primary endpoint demonstrating strong immune response and favorable safety profileMeiji Seika Pharma submitted ARCT-154 New Drug Application in JapanNew ARCT-154 booster clinical data demonstrate one-year durability across a panel of variantsReceived FDA Fast Track De...

Related Keywords

Meiji ,Hokkaido ,Japan ,New Zealand ,California ,United States ,San Diego ,United Kingdom ,China ,Israel ,Japanese ,Israeli ,Joseph Payne ,Seika Pharma ,Neda Safarzadeh ,Carlo Tanzi ,Drug Administration ,Twitter ,Israeli Ministry Of Health ,Linkedin ,Co Ltd ,Therapeutics Holdings Inc ,Nasdaq ,Mrna Technology ,Arcturus Therapeutics Holdings Inc ,Drug Application ,Track Designation ,Rare Pediatric Disease Designation ,Clinicaltrial Arcturus Therapeutics Holdings ,Meiji Seika Pharma ,Fast Track Designation ,Six Months Ended June ,Israeli Ministry ,Administrative Expenses ,Balance Sheet ,Arcturus Therapeutics Holdings ,Private Securities Litigation Reform Act ,Annual Report ,